A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer - PubMed (original) (raw)

Multicenter Study

. 2009 Jul;18(7):2046-53.

doi: 10.1158/1055-9965.EPI-09-0235. Epub 2009 Jun 30.

Mimi Kim, Rowan T Chlebowski, Janu Khandekar, Marcia G Ko, Anne McTiernan, Marian L Neuhouser, Donna R Parker, James M Shikany, Marcia L Stefanick, Cynthia A Thomson, Thomas E Rohan

Affiliations

Multicenter Study

A longitudinal study of the metabolic syndrome and risk of postmenopausal breast cancer

Geoffrey C Kabat et al. Cancer Epidemiol Biomarkers Prev. 2009 Jul.

Abstract

The metabolic syndrome, characterized by abdominal obesity, high blood glucose levels, impaired glucose tolerance, dyslipidemia, and hypertension, is associated with increased risk of type 2 diabetes and coronary heart disease. Several studies have examined the association of the individual components of the metabolic syndrome with breast cancer; to date, however, no study has assessed the metabolic syndrome per se in relation to breast cancer risk. Furthermore, previous studies have relied only on baseline assessment of components of the syndrome. Therefore, we assessed the association of the metabolic syndrome with the risk of postmenopausal breast cancer among women in the 6% sample of subjects in the Women's Health Initiative clinical trial and the 1% sample of women in the observational study who had repeated measurements of the components of the syndrome during follow-up. We used Cox proportional hazards models to estimate hazard ratios and 95% confidence intervals for the association of breast cancer risk with the presence of the metabolic syndrome, as well as its components, at baseline and in time-dependent analyses. After exclusion of women with diabetes, among 4,888 women with baseline measurements, 165 incident cases of breast cancer were ascertained over a median of 8 years of follow-up. The presence of the metabolic syndrome at baseline was not associated with altered risk. Of the individual components measured at baseline, diastolic blood pressure showed a borderline positive association with breast cancer. In time-dependent covariate analyses, however, certain scenarios indicated a positive association between the metabolic syndrome and breast cancer, due primarily to positive associations with serum glucose, serum triglycerides, and diastolic blood pressure.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Sathyaprakash R, Henry RR. Preventing diabetes by treating aspects of the metabolic syndrome. Curr Diab Rep 2002;2:416–22. - PubMed
    1. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210–14. - PubMed
    1. Meigs JB, Wilson PWF, Nathan DM, D’Agostino RB Sr, Williams K, Haffner SM. Prevalence and characteristics of the metabolic syndrome in the San Antonio heart and Framingham offspring studies. Diabetes 2003;52:2160–67. - PubMed
    1. Xue F, Michels KB. Diabetes, metabolic syndrome, and breast cancer: a review of the current evidence. Am J Clin Nutr 2007;86:823S–35S. - PubMed
    1. Goodwin PJ, Ennis M, Bahl M, et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat 2008. April 25 [Epub ahead of print]. - PubMed

Publication types

MeSH terms

LinkOut - more resources